Global Intravenous (IV) Iron Drugs Strategic Business Report 2018: 2016-2024 Market Analysis & Forecast - ResearchAndMarkets.com

DUBLIN--()--The "Intravenous (IV) Iron Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets.

This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Thousand.

The report profiles 21 companies including many key and niche players such as:

  • Allergan Plc. (Ireland)
  • AMAG Pharmaceuticals, Inc. (USA)
  • Daiichi Sankyo, Inc. (USA)
  • Luitpold Pharmaceuticals, Inc. (USA)
  • American Regent, Inc. (USA)
  • Pharmacosmos A/S (Denmark)
  • Sanofi US (USA)
  • Vifor Pharma Ltd. (Switzerland)
  • Vifor Fresenius Medical Care Renal Pharma (Switzerland)

Key Topics Covered

1. GLOBAL MARKET OVERVIEW

2. GROWTH DRIVERS & MARKET TRENDS

  • Expanding Pool of ESRD and CKD Patients
  • The Major Growth Driver for Intravenous (IV) Iron Drugs
  • ESRD Prevalence Statistics: An Opportunity Indicator
  • Increase in Healthcare Spending Bodes Well for Intravenous Iron Drugs Market
  • Dialysis Patients
  • A Major Market for Intravenous Iron Supplements
  • Ageing Population Drives Demand for IV Iron Drugs
  • Shifting Preference from Oral Iron Drugs to Intravenous Iron Drugs
  • Comparison of Ferrous Salts with IV Iron Therapy
  • Other Chronic Diseases with IDA Offer Prospects for IV Iron Drugs
  • Anemia in Heart Failure
  • A Market with Huge Potential
  • Chemotherapy Induced Anemia to Promote IV Iron Supplements
  • Correction of IDA in Pregnancy Signals Opportunities
  • Women’s Health
  • A Key Growth Opportunity
  • Perioperative and Postoperative Anemia
  • A Niche Market Beckons
  • Adverse Reactions of IV Iron Preparations Raise Concerns
  • Dosing Limitations Plague IV Iron Market
  • Select Therapeutic Areas and the Required Iron Doses

3. REGULATORY OVERVIEW

4. OVERVIEW OF INTRAVENOUS (IV) IRON DRUGS

5. RECENT INDUSTRY ACTIVITY

6. FOCUS ON SELECT PLAYERS

7. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 21 (including Divisions/Subsidiaries 22)

The United States ((5)

Japan (2)

Europe (7)

- France (1)

- Germany (1)

- The United Kingdom (1)

- Rest of Europe (4)

Asia-Pacific (Excluding Japan) (8)

For more information about this report visit https://www.researchandmarkets.com/research/637g4n/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infusions and Injectables, Hematological Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infusions and Injectables, Hematological Drugs